Summary of Financial Statements for the Nine Month Period Ended December 31, 2013 (Japan GAAP, Consolidated)

February 5, 2014

Takeda Pharmaceutical Company Limited Stock exchange listings: Tokyo, Nagoya, Fukuoka, Sapporo

TSE Code: 4502 URL: http://www.takeda.co.jp
Representative: Yasuchika Hasegawa, President & CEO
Contact: Christopher Hohman Telephone: +81-3-3278-2037
Senior Vice President,
Corporate Communications Department

Scheduled date of securities report submission: February 14, 2014
Scheduled date of dividend payment commencement: —
Supplementary materials for the quarterly financial statements: Yes
Presentation to explain for the quarterly financial statements: Yes

(Millions of yen, rounded to the nearest million)

1. Consolidated Financial Results for the Nine Month Period Ended December 31, 2013 (April 1 to December 31, 2013)

(1) Consolidated Operating Results (year to date)

(Percentage figures represent changes over the same period of the previous year)

	Net sales		Operating income		Ordinary income		Net income	
	(¥ million)	change (%)	(¥ million)	change (%)	(¥ million)	change (%)	(¥ million)	change (%)
Nine month period ended December 31, 2013	1,286,875	8.2	169,357	12.4	156,935	3.7	110,998	(20.1)
Nine month period ended December 31, 2012	1,189,109	5.5	150,672	(43.1)	151,300	(42.9)	138,912	(13.5)

(Note) Comprehensive income Nine month period ended December 31, 2013 ¥ 371,504 million (82.8 %)
Nine month period ended December 31, 2012 ¥ 203,255 million (－%)

	Earnings per share (¥)	Fully diluted earnings per share (¥)
Nine month period ended December 31, 2013	140.60	140.45
Nine month period ended December 31, 2012	175.96	175.93

(2) Consolidated Financial Position

	Total assets (¥ million)	Net assets (¥ million)	Shareholders' equity ratio (%)	Shareholders' equity per share (¥)
As of December 31, 2013	4,425,786	2,453,243	53.8	3,016.64
As of March 31, 2013	3,955,599	2,223,359	54.6	2,734.79

(Reference) Shareholders' equity As of December 31, 2013 ¥ 2,381,547 million
As of March 31, 2013 ¥ 2,159,006 million

2. Dividends

	Annual dividend per share (¥)				
	1st quarter end	2nd quarter end	3rd quarter end	Year-end	Total
Fiscal 2012	—	90.0	—	90.0	180.0
Fiscal 2013	—	90.0	—		
Fiscal 2013 (Projection)				90.0	180.0

(Note) Modifications in the dividend projection from the latest announcement: None

3. Forecasts for Consolidated Operation Results for Fiscal 2013 (April 1, 2013 to March 31, 2014)

(Percentage figures represent changes over the same period of the previous year)

	Net sales		Operating income		Ordinary income		Net income		Earnings per share
	(¥ million)	change (%)	(¥ million)	change (%)	(¥ million)	change (%)	(¥ million)	change (%)	(¥)
Fiscal 2013	1,690,000	8.5	150,000	22.4	135,000	19.3	100,000	(23.8)	126.67

(Note) Modifications in forecasts of consolidated operating results from the latest announcement: Modified

Additional Information

(1) Changes in significant subsidiaries during the period : No
(changes in specified subsidiaries resulting in the change in consolidation scope)

(2) Adoption of special accounting treatments for quarterly consolidated financial statements: Yes
(Note) For details, refer to "2. Additional Information in Summary" in Page 15

(3) Changes in accounting policies, changes in accounting estimates and restatements
1) Changes in accounting policies due to revisions of accounting standards, etc. : No
2) Changes in accounting policies other than 1) : No
3) Changes in accounting estimates : No
4) Restatements : No

(4) Number of shares outstanding (common stock)
1) Number of shares outstanding (including treasury stock) at term end:

December 31, 2013	789,680,595 shares
March 31, 2013	789,666,095 shares

2) Number of shares of treasury stock at term end:

December 31, 2013	211,540 shares
March 31, 2013	205,831 shares

3) Average number of outstanding shares (for the nine month period ended December 31):

December 31, 2013	789,463,563 shares
December 31, 2012	789,431,149 shares

* Implementation status about the quarterly review

- This summary of financial statements is exempt from quarterly review procedures required by Financial Instruments and Exchange Act. A part of quarterly review for securities report based on Financial Instruments and Exchange Act has not finished at the time of disclosure of this summary of financial statements. The securities report for the nine month period ended December 31, 2013 is scheduled to be disclosed on February 14, 2014 after completion of the quarterly review.

* Note to ensure appropriate use of forecasts, and other comments in particular

- Our operations are exposed to various risks at present and in the future, such as changes in the business environment and fluctuation of foreign exchange rates. All forecasts in this presentation are based on information currently available to the management, and various factors could cause actual results to differ. We will disclose necessary information in a timely manner when our management believes there will be significant impacts to our consolidated results due to changes in the business environment or other events.
- Regarding the assumptions made and the items to be considered in the financial forecasts, please refer to "1. Qualitative Information for the Nine Month Period Ended December 31, 2013 (3) Outlook for Fiscal 2013" on Page 15.
- Takeda has decided to voluntarily adopt International Financial Reporting Standards (IFRS) from the year-end earnings announcement of Fiscal 2013. For details, and for estimated consolidated financial results for the nine month period ended December 31, 2013 calculated under IFRS reflecting the major differences between Japanese Generally Accepted Accounting Principles and IFRS accounting, please refer to pages 23, 37 and 38 of the quarterly supplementary material, "Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2013."
- Presentation materials for the earnings release conference which is scheduled on February 5, 2014 and the audio of the conference including question-and-answer session will be promptly posted on the Company's website.
  (Website of the Company)
  http://www.takeda.com/investor-information/results/

Attachment Index

1.Qualitative Information for the Nine Month Period Ended December 31, 2013

(1) Consolidated Operating Results

(i) Overview

While the U.S. economy continues to experience a mild recovery, Europe has not yet fully recovered from economic stagnation in the wake of the debt crisis and emerging markets are experiencing a slowing down of economic growth, resulting in a global economy that remains unpredictable. Meanwhile, in Japan domestic demand is stable and the economy is gradually recovering with the support of the Japanese government’s fiscal policies and monetary easing by the Bank of Japan.

In the global pharmaceutical market, particularly in developed countries, sales growth has slowed due to factors including blockbuster products being replaced by generics after patent expiry, and increasingly severe policies to constrain healthcare expenditures arising from government financial reforms. In the area of Research & Development, companies have been facing challenges in innovative drug discovery and technological breakthroughs as well as increasingly stringent regulatory criteria for new drug approvals. However, there are high expectations for new products that address currently unmet medical needs, and the practical application of regeneration medical technology, such as iPS cell technology.

In light of these circumstances, Takeda Pharmaceutical Company Limited ("Takeda", "the Company"), as a global company, formulated “Vision 2020” last spring to articulate our aspiration of where we want the Company to be in the year 2020. The objective of Takeda's business is to "pursue innovative medicines as well as high-quality branded generics, life-saving vaccines, and OTC medicines - to help as many people as we can, as soon as we can."

To realize Vision 2020, Takeda initiated a Mid-Range Growth Strategy starting from fiscal 2013 that is further deepening and expanding previous strategies, centered around the core principles of "Globalization," "Diversity" and "Innovation." In particular, Takeda will focus on maximizing sales through leveraging a broad portfolio of products and markets and also on steadily progressing our extremely competitive late stage pipeline. In parallel to this, Takeda is continuing to build a robust and efficient operating model suitable for a global pharmaceutical company with measures such as the appointment of a CFO (Chief Financial Officer) and GHRO (Global Human Resources Officer) during this fiscal year. Takeda will leverage their various global experiences and further reinforce Project Summit, a Takeda-wide strategic initiatives optimizing the effectiveness and efficiency of our entire operations which will lead to driving sales and profit growth.

<Commercial Initiatives>

In developed countries, Takeda is promoting a shift in product portfolio towards new products, while in emerging markets, in addition to launching new in-house products, Takeda aims to acquire and promote diverse portfolios tailored to local needs in order to achieve sales growth that exceeds the market growth in each region.

In the U.S., Takeda is striving to maximize the sales of new products for the treatment of type 2 diabetes which were launched in June 2013: NESINA (a dipeptidyl peptidase-4 inhibitor (DPP-4i)), KAZANO (a fixed-dose combination of NESINA and metformin), and OSENI (a fixed-dose combination of NESINA and the thiazolidinedione (TZD) ACTOS) which is the first product in the U.S. to include both a DPP-4i and TZD in a single tablet. In September 2013, Takeda began marketing of BRINTELLIX in January 2014, following the New Drug Application (NDA) approval for BRINTELLIX for the treatment of major depressive disorder (MDD) in September 2013. BRINTELLIX

is a new antidepressant drug, and because higher doses demonstrated better treatment effects in trials conducted in the U.S., it offers flexibility for physicians to help address the variability of patient needs.

In Europe, Takeda has finished the consolidation of commercial subsidiaries in overlapping areas with legacy Nycomed, and furthermore, the Company is promoting strategic measures to improve efficiency through the consolidation of manufacturing and R&D facilities, achieving cost reduction synergies. In addition, the sales of ADCETRIS for the treatment of lymphoma are significantly expanding. In December 2013, Takeda presented updated data from a clinical trial evaluating ADCETRIS in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large cell lymphoma which demonstrated extended survival among this heavily pretreated patient population.

In Japan, Takeda is striving to maximize the sales of strategic products such as the NESINA family for the treatment of type 2 diabetes and AZILVA for the treatment of hypertension. In particular, prescriptions for AZILVA are increasing after the restriction on long-term prescriptions was lifted in May 2013. Also, Takeda has entered into an agreement with the Research Foundation for Microbial Diseases of Osaka University ("BIKEN") in Japan for the sale of BIKEN varicella vaccine in Japan, which will commence sales in February 2014.

In emerging countries, Takeda is striving to further expand its commercial platform in growing markets with the establishment of wholly-owned subsidiary in Israel this fiscal year.

<R&D Initiatives>

Takeda is committed to the discovery and delivery of innovative solutions addressing unmet medical needs of patients through R&D investment. Based on this core value, Takeda is striving to progress the rich late-stage pipeline successful towards new drug approvals. Major R&D achievements in this fiscal year by region are as follows:
In the U.S. in June 2013, Takeda submitted a Biologics License Application for MLN0002 (generic name: vedolizumab) for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). In December 2013, a joint panel of members from the U.S. Food and Drug Administration (FDA) voted to recommend approval of Takeda's vedolizumab for both UC and CD indications.
In Europe, Takeda obtained approval of the Marketing Authorization Application by Swissmedic for atypical antipsychotic medication lurasidone hydrochloride in August 2013, and began marketing in September. Also in September 2013, Takeda was granted Marketing Authorization by the European Commission for VIPIDIA*, VIPDOMET**, and INCRESYNC*** and began marketing in November 2013.
In China in July 2013, Takeda obtained an Import Drug License from the China Food and Drug Administration for NESINA for the treatment of type 2 diabetes and began marketing in December 2013.
In Japan, in September 2013, Takeda obtained the NDA approval from the Japanese Ministry of Health, Labour and Welfare for OBLEAN for the treatment of obesity with certain complications. In addition, in December 2013, Takeda submitted an NDA for fomepizole (generic name), a treatment for ethylene glycol and methanol poisonings. Also in January 2014, Takeda obtained the NDA approval of ADCETRIS for the treatment for adult patients with CD30 positive relapsed/refractory Hodgkin Lymphoma and relapsed/refractory anaplastic large cell lymphoma.

Furthermore, in the vaccine business, Takeda acquired Inviragen, Inc. of the U.S. in May 2013 with its pipeline assets including a vaccine for dengue fever. In addition in September 2013, Takeda submitted a New Drug Application in Japan for TAK-816, a vaccine against infections caused by Haemophilus influenzae type b (Hib).

Moving forward, Takeda will continue striving to further enhance R&D productivity with improved cost effectiveness, not only through internal R&D efforts but also through business development initiatives such as alliance activities or joint research with external partners.

For further details of R&D activities, please refer to section (iv) "Activities and Results of Research & Development" on page 11.

* Japan and U.S. product name: NESINA, ** U.S. product name: KAZANO, *** Japan product name: LIOVEL, U.S. product name: OSENI.

Based on the corporate philosophy of "Takeda-ism" (Integrity: Fairness, Honesty and Perseverance) developed over its long corporate history of more than 230 years, Takeda strives to ensure compliance with laws and regulations governing its operations, and conducts activities according to the corporate mission to "strive towards better health for people worldwide through leading innovation in medicine."

<Reference> Major products launched in and after 2010

[Japan]

Launched in 2010	
Nesina	a drug for type 2 diabetes, generic name: alogliptin benzoate
Unisia	a drug for treatment of hypertension: a fixed dose combination of Blopress and a calcium channel blocker (amlodipine besilate)
Vectibix	a cancer drug, generic name: panitumumab
Rozerem	an insomnia drug, generic name: ramelteon
Metact	a drug for type 2 diabetes: a fixed dose combination of Actos and a biguanide (metformin hydrochloride)
Actos OD (orally-disintegrating tablets)	a drug for type 2 diabetes
Lampion pack	a drug for secondary eradication of Helicobacter Pylori: a single pack containing Takepron, amoxicillin hydrate and metronidazole
Launched in 2011	
Reminyl	a drug for Alzheimer's dementia, generic name: galantamine hydrobromide, licensed from Janssen and jointly marketed with the licensor
Sonias	a drug for type 2 diabetes: a fixed dose combination of Actos and a sulfonylurea (glimepiride)
Liovel	a drug for type 2 diabetes: a fixed dose combination of Nesina and Actos
Launched in 2012	
Azilva	a drug for treatment of hypertension, generic name: azilsartan
Launched in January 2013	
Lotriga	a drug for treatment of hyperlipidemia, generic name: omega-3-acid ethyl esters 90

[North America]

<U.S.A.>

Launched in 2010	
Actoplus met XR	a drug for type 2 diabetes: a fixed dose combination of Actos and a biguanide (metformin extended- release)
Launched in 2011	
Edarbi	a drug for treatment of hypertension, generic name: azilsartan medoxomil
Launched in 2012	
Edarbyclor	a drug for treatment of hypertension, a fixed dose combination of Edarbi and a thiazide diuretic (chlorthalidone)
Launched in June 2013	
Nesina	a drug for type 2 diabetes, generic name: alogliptin benzoate
Kazano	a drug for type 2 diabetes: a fixed dose combination of Nesina and a biguanide (metformin hydrochloride)
Oseni	a drug for type 2 diabetes: a fixed dose combination of Nesina and Actos
Launched in January 2014	
Brintellix	a drug for treatment of adult patients with major depressive disorder, generic name: vortioxetine

<Canada>

Launched in 2010	
Dexilant	a drug for acid reflux disease, generic name: dexlansoprazole
Uloric	a drug for hyperuricemia for patients with chronic gout, generic name: febuxostat
Launched in 2011	
Daxas	a drug for chronic obstructive pulmonary disease, generic name: roflumilast
Launched in 2012	
Feraheme	a drug for treatment of iron deficiency anaemia, generic name: ferumoxytol

[Europe]

Launched in 2010	
Mepact	a drug for non-metastatic osteosarcoma, generic name: mifamurtide
Launched in 2012	
Edarbi	a drug for treatment of hypertension, generic name: azilsartan medoxomil
Rienso	a drug for treatment of iron deficiency anaemia, generic name: ferumoxytol
Adcetris	a drug for treatment of relapsed/refractory CD30 positive Hodgkin lymphoma and relapsed/refractory systemic anaplastic large cell lymphoma, generic name: brentuximab vedotin
Launched in September 2013	
Latuda	an atypical antipsychotic, generic name: lurasidone hydrochloride
Launched in November 2013	
Vipidia	a drug for type 2 diabetes, generic name: alogliptin benzoate
Vipdomet	a drug for type 2 diabetes: a fixed dose combination of Nesina and a biguanide (metformin hydrochloride)
Incresync	a drug for type 2 diabetes: a fixed dose combination of Nesina and Actos

[Emerging markets]

<Brazil>

Launched in 2011	
Daxas	a drug for chronic obstructive pulmonary disease, generic name: roflumilast

<Russia>

Launched in 2012	
Daxas	a drug for chronic obstructive pulmonary disease, generic name: roflumilast

<Mexico>

Launched in 2011	
Dexilant	a drug for acid reflux disease, generic name: dexlansoprazole
Mepact	a drug for non-metastatic osteosarcoma, generic name: mifamurtide
Launched in 2012	
Edarbi	a drug for treatment of hypertension, generic name: azilsartan medoxomil
Launched in January 2013	
Daxas	a drug for chronic obstructive pulmonary disease, generic name: roflumilast
Launched in March 2013	
Edarbyclor	a drug for treatment of hypertension, a fixed dose combination of Edarbi and a thiazide diuretic (chlorthalidone)

<China>

Launched in December 2013	
Nesina	a drug for type 2 diabetes, generic name: alogliptin benzoate

(ii) Operating Results

Consolidated results (April 1 to December 31, 2013):

Billions of yen

	Amount	*Change over the same period of the previous year*
Net Sales	1,286.9	+ 97.8 [+8.2%]
Operating Income	169.4	+ 18.7 [+12.4%]
Ordinary Income	156.9	+5.6 [+3.7%]
Net Income	111.0	-27.9 [-20.1%]

[Net Sales]

Over the nine month period ended December 31, 2013, consolidated net sales were ¥1,286.9 billion, an increase of ¥97.8 billion (8.2%) compared to the same period of the previous year.

- In Japan, the sales of AZILVA (a drug for hypertension) launched in 2012 and NESINA (a drug for type 2 diabetes) increased. In the U.S, in addition to the sales contribution of COLCRYS (a drug for hyperuricemia and gout) which was acquired with the URL acquisition in June 2012, the sales of VELCADE (a drug for multiple myeloma) and DEXILANT (a drug for acid reflux disease) increased. Furthermore, the sales of ADCETRIS (a drug for lymphoma) significantly expanded in Europe, and sales in emerging markets including Asia also increased mainly due to the sales contribution of PANTOPRAZOLE (a drug for peptic ulcer). Such positive factors and the yen's depreciation (positive impact: ¥121.5 billion) absorbed the drastic decrease in sales of ACTOS (a drug for type 2 diabetes) in the U.S. (¥ -79.7 billion) due to the penetration of generic products after the patent expiry.

  In total, consolidated net sales increased by ¥97.8 billion.

- Consolidated sales of Takeda's major ethical drugs:

Billions of yen

Indications / Product Name	Amount	Change over the same period of the previous year
Hypertension / Candesartan (Japan product name: Blopress)	122.9	-9.9 [-7.5%]
Prostate cancer, breast cancer and endometriosis / Leuprorelin (Japan product name: Leuplin)	95.9	+8.2 [+9.4%]
Peptic ulcer / Lansoprazole (Japan product name: Takepron)	90.1	+4.5 [+5.2%]
Peptic ulcer / Pantoprazole	77.2	+20.7 [+36.7%]
Multiple myeloma / Velcade (U.S. sales)	71.4	+17.5 [+32.5%]
Hyperuricemia and gout / Colcrys (U.S. sales)	38.1	+15.3 [+66.7%] (see Note below)
Type 2 diabetes / Pioglitazone (Japan product name: Actos)	29.5	-79.7 [-73.0%]

(Note) As for Colcrys which was acquired with the URL acquisition in June 2012, the comparative sales amount before the acquisition (from April to May 2012) is not included.

[Operating Income]

Consolidated operating income was ¥169.4 billion, an increase of ¥18.7 billion (12.4%) compared to the same period of the previous year.

- Selling, general and administrative expenses increased by ¥56.3 billion (8.0%) compared to the same period of the previous year mainly due to the yen's depreciation (negative impact: ¥109.7 billion), while gross profit increased by ¥75.0 billion (8.8%) due to sales increase. As a result, operating income increased.
- R&D expenses were ¥238.2 billion, an increase of ¥6.6 billion (2.9%) compared to the same period of the previous year.
- Selling, general and administrative expenses, excluding R&D expenses increased by ¥49.7 billion (10.6%) to ¥520.0 billion compared to the same period of the previous year mainly due to the yen's depreciation, despite cost saving by the effect of restructuring in overseas subsidiaries.
- Operating income excluding special factors (see Note below) was ¥283.5 billion, an increase of ¥28.2 billion (11.1%) compared to the same period of the previous year.
  (Note) Operating income excluding special factors is calculated by deducting any special factors such as amortization of goodwill and intangible assets due to business acquisitions from operating income.

[Ordinary Income]

Consolidated ordinary income was ¥156.9 billion, an increase of ¥5.6 billion (3.7%) compared to the same period of the previous year.

- The increase in operating income absorbed the unfavorable changes in net non-operating income/expenses of ¥13.1 billion mainly derived from the increase in foreign exchange losses. As a result, ordinary income increased.

[Net Income]

Consolidated net income was ¥111.0 billion, a decrease of ¥27.9 billion (20.1%) compared to the same period of the previous year.

- In addition to the increase in ordinary income, the company recorded net extraordinary income/losses of ¥23.3 billion (see Note below). On the other hand, the tax refunds of ¥52.8 billion (including interest) relating to the correction for transfer pricing taxation were included in the same period of the previous year. As a result, consolidated net income decreased.
  (Note) Gain on sales of investment securities [gain ¥37.4 billion], Restructuring costs [loss ¥14.0 billion]
- Earnings per share ("EPS") was ¥140.60, a decrease of ¥35.36 (20.1%) compared to the same period of the previous year.
- Net income excluding extraordinary income (loss) and special factors (see Note below) was ¥191.2 billion, an increase of ¥23.6 billion (14.1%) compared to the same period of the previous year, and EPS based on this income was ¥242.18, an increase of ¥29.93 (14.1%) compared to the same period of the previous year.
  (Note) Net income excluding extraordinary income (loss) and special factors is calculated by deducting any extraordinary income (loss), special factors such as amortization of goodwill and intangible assets due to business acquisitions and the tax refund related to transfer price taxation from net income.

(iii) Results by Segment

Sales and operating income by business segment (April 1 to December 31, 2013):

Billions of yen

Type of Business	Net sales		Operating income	
	Amount	Change over the same period of the previous year	Amount	Change over the same period of the previous year
Ethical Drug	1,163.4	+92.8	143.0	+13.4
<Japan>	<454.1>	< -5.1>		
<Overseas>	<709.3>	<+97.9>		
Consumer Healthcare	57.3	+4.2	16.6	+3.2
Other	69.3	+0.5	10.9	+1.7
Total	1,286.9	+97.8	169.4	+18.7

(Note) Net sales for each segment refer to sales to outside customers.

[Ethical Drug Business]

Net sales in the Ethical Drug Business were ¥1,163.4 billion, an increase of ¥92.8 billion (8.7%) compared to the same period of the previous year, and operating income was ¥143.0 billion, an increase of ¥13.4 billion (10.3%).

- Net sales in Japan were ¥454.1 billion, a decrease of ¥5.1 billion (1.1%) compared to the same period of the previous year. Contribution from sales increase of products launched in and after 2010 such as NESINA and AZILVA could not fully absorb the drop in sales of ACTOS and BLOPRESS, and the distribution sales decline due to the expiration of distribution agreement for some products.

- The following table shows sales results of major products in Japan:

Billions of yen

Product Name (Indications)	Amount	Change over the same period of the previous year
Blopress (Hypertension)	100.0	-4.1 [-4.0%]
Takepron (Peptic ulcer)	54.0	+0.3 [+0.6%]
Leuplin (Prostate cancer, breast cancer and endometriosis)	51.2	+0.4 [+0.9%]
Nesina (Type 2 diabetes)	29.5	+3.7 [+14.5%]
Azilva (Hypertension)	15.9	+13.7 [+638.8%]
Vectibix (Cancer)	14.8	+0.1 [+0.8%]
Actos (Type 2 diabetes)	12.5	-2.8 [-18.1%]

- Sales in overseas markets were ¥709.3 billion, an increase of ¥97.9 billion (16.0%) compared to the same period of the previous year. The sales of COLCRYS accompanied by the URL acquisition and the sales expansion in emerging markets including Asia contributed to the sales increase. Such positive factors and the yen's

depreciation absorbed the significant decline in sales of Pioglitazone and Candesartan due to the market entry of generic products in U.S. and Europe.

- The following table shows sales results of major products in overseas markets:

Billions of yen

Product Name (Indications)	Amount	Change over the same period of the previous year
Pantoprazole (Peptic ulcer)	77.2	+20.7 [+36.7%]
Velcade (Multiple myeloma)	71.4	+17.5 [+32.5%]
Leuprorelin (Prostate cancer, breast cancer and endometriosis)	44.7	+7.8 [+21.1%]
Colcrys (Hyperuricemia and gout)	38.1	+15.3 [+66.7%] (see Note below)
Dexilant (Acid reflux disease)	36.2	+12.7 [+54.2%]
Lansoprazole (Peptic ulcer)	36.1	+4.1 [+12.9%]
Candesartan (Hypertension)	23.0	-5.8 [-20.1%]
Pioglitazone (Type 2 diabetes)	17.0	-76.9 [-81.9%]

(Note) As for Colcrys which was acquired with the URL acquisition in June 2012, the comparative sales amount before the acquisition (from April to May 2012) is not included.

[Consumer Healthcare Business]

Net sales in the Consumer Healthcare Business were ¥57.3 billion, an increase of ¥4.2 billion (7.9%) compared to the same period of the previous year, mainly due to the increase in sales of ALINAMIN tablets and health tonics (vitamin-containing products) and BENZA medicines (combination cold remedies). Operating income increased by ¥3.2 billion (24.2%) to ¥16.6 billion mainly due to the increase in gross profit accompanied by sales growth.

[Other Business]

Net sales in the Other Business were ¥69.3 billion, an increase of ¥0.5 billion (0.7%) compared to the same period of the previous year, and operating income increased by ¥1.7 billion (18.8%) to ¥10.9 billion mainly due to the decrease in expenses.

(iv) Activities and Results of Research & Development

Takeda has made steady progress in improving R&D productivity with the R&D strategy taking on two key initiatives, "*Quality of Thought*" and "*Operational Excellence*", to build on the four guiding R&D principles of operation: "*Urgency*", "*Innovation*", "*Measurement*" and "*Partnership*". Based on our strengths and the latest unmet medical needs, Takeda has 6 core therapeutic areas of Cardiovascular & Metabolic, Oncology, Central Nervous System, Immunology & Respiratory, General Medicine and Vaccine, with focused resource investment towards leading innovation. Takeda continues efforts to further enhance R&D productivity by focusing on the pipeline in the core therapeutic areas with specific strategies for the short-, mid- and long-term (leveraging the advantage of a rich late-stage pipeline, filling the gap in the mid-stage portfolio, and strengthening research competiveness & productivity, respectively). In line with our R&D strategy as well as for building a more robust and efficient operating model in R&D, in May 2013, the oncology R&D functions were integrated into the CMSO organization from our 100% subsidiary Millennium Pharmaceuticals, Inc.
Major achievements from R&D activities during the reporting period are as follows;

[In-house R&D activities]

- In April 2013, Takeda submitted a New Drug Application (NDA) for the fixed-dose combination (FDC) of AZILVA (generic name: azilsartan) and amlodipine besylate to the Japanese Ministry of Health, Labour and Welfare.

- In June 2013, Takeda presented results of a Phase I clinical trial evaluating single agent MLN9708 (generic name: ixazomib citrate) in patients with relapsed and/or refractory multiple myeloma (MM), at the annual meeting of the American Society of Clinical Oncology (ASCO).
  In November 2013, Takeda initiated enrollment of patients in Japan in an ongoing global Phase III clinical trial (TOURMALINE-MM1 study) of MLN9708 in relapsed and/or refractory MM.
  In December 2013, Takeda presented final Phase I and preliminary Phase II results of a study combining MLN9708 administered with lenalidomide and dexamethasone in patients with previously untreated MM at the 55th American Society of Hematology (ASH) annual meeting.

- In June 2013, Takeda submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MLN0002 (generic name: vedolizumab) for the treatment of adults with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC), and in September 2013, the FDA granted Priority Review status for MLN0002 for the treatment of adults with moderately to severely active UC.
  In December 2013, a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the FDA voted to recommend approval of MLN0002 for the treatment of adults with moderately to severely active UC and CD. In December 2013, the FDA extended the Prescription Drug User Fee Act (PDUFA) Priority Review action date for the UC indication of MLN0002.
  In January 2014, Takeda initiated two Phase III clinical trials in Japan for MLN0002 for the treatment of moderate and severe UC and CD.
  In August 2013, results of Phase III clinical trials evaluating MLN0002 were published in the *New England Journal of Medicine*.

- In July 2013, Takeda unblinded the ELM-PC 5 (Evaluation of the Lyase inhibitor orteronel in Metastatic Prostate Cancer 5) (C21005) global Phase III study of TAK-700 (generic name: orteronel) in patients with metastatic,

castration-resistant prostate cancer that had progressed during or following chemotherapy based on the recommendation of the independent data monitoring committee. The pre-specified interim analysis indicated that TAK-700 plus prednisone would likely not meet the primary endpoint of improved overall survival when compared to the control arm. The interim analysis did show an advantage for TAK-700 plus prednisone for the secondary endpoint, radiographic progression-free survival over the control arm. In addition, there were no safety concerns.

- In July 2013, Takeda received a positive opinion from the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) for VIPIDIA (generic name: alogliptin), VIPDOMET, an FDC of VIPIDIA and metformin, and INCRESYNC, an FDC of VIPIDIA and pioglitazone, for the treatment of type 2 diabetes. In September 2013, the European Commission (EC) granted Marketing Authorization for these products.
  In July 2013, Takeda obtained an Import Drug License (IDL) from the China Food and Drug Administration (CFDA) for NESINA (generic name: alogliptin) for the treatment of type 2 diabetes.
  In September 2013, Takeda presented results of the EXAMINE cardiovascular safety outcomes trial for alogliptin at the European Society of Cardiology (ESC) Congress. These data were also published in the *New England Journal of Medicine*.

- In October 2013, Takeda presented results of a Phase I/II study of its intramuscular bivalent (GI/GII) norovirus vaccine candidate in healthy adult volunteers at Infectious Disease Week 2013.

- In December 2013, Takeda presented overall survival data from a Phase III VISTA study of VELCADE (generic name: bortezomib) in patients with previously untreated MM at the 55th ASH annual meeting.

- In December 2013, Takeda decided to terminate the global development activities for TAK-875 (generic name: fasiglifam), due to concerns about liver safety.

[Alliance activities]

- In May 2013, Takeda and H. Lundbeck A/S (Lundbeck) presented results of Phase III clinical trials evaluating BRINTELLIX (generic name: vortioxetine), which Takeda in-licensed from Lundbeck of Denmark, in adult patients with major depressive disorder (MDD), at the 166th American Psychiatric Association Annual Meeting (APA). In September 2013, Takeda obtained approval from the FDA for BRINTELLIX for the treatment of adult patients with MDD.

- In June 2013, Takeda presented interim data from a Phase I portion of Phase I/II clinical trials evaluating ADCETRIS (generic name: brentuximab vedotin), which Takeda in-licensed from Seattle Genetics, Inc. of the U.S., in pediatric patients diagnosed with CD30-positive relapsed or refractory Hodgkin lymphoma (HL) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL), at ASCO.
  In December 2013, Takeda presented updated overall survival data from two ADCETRIS pivotal Phase II clinical trials in relapsed/refractory HL and relapsed/refractory sALCL at the 55th ASH annual meeting.
  In January 2014, Takeda obtained approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS, for the treatment for patients with CD30 positive relapsed or refractory HL or relapsed or refractory anaplastic large cell lymphoma (ALCL).

- In July 2013, Takeda withdrew the European Marketing Authorization Application (MAA) submitted in February 2012 for peginesatide, which Takeda in-licensed from Affymax, Inc. of the U.S., intended to be used for treatment of symptomatic anaemia associated with chronic kidney disease in adult patients undergoing dialysis.

- In July 2013, Takeda and Zinfandel Pharmaceuticals, Inc. of the U.S. presented new data on the performance characteristics of a genetics-based biomarker risk assignment algorithm including TOMM40 to identify the risk of developing mild cognitive impairment due to Alzheimer's disease, at the Alzheimer's Association International Conference (AAIC). In August 2013, Takeda initiated a Phase III clinical trial, TOMMORROW, for AD-4833 (generic name: pioglitazone)/TOMM40.

- In August 2013, Takeda obtained approval of the MAA by Swissmedic in Switzerland for atypical antipsychotic medication lurasidone hydrochloride (generic name), which Takeda in-licensed from Dainippon Sumitomo Pharma Co., Ltd. of Japan, for the treatment of patients with schizophrenia. In January 2014, Takeda received a positive opinion from the CHMP of the EMA for lurasidone hydrochloride.

- In September 2013, Takeda obtained approval from the Japanese Ministry of Health, Labour and Welfare for OBLEAN (generic name: cetilistat), which Takeda in-licensed from Norgine BV of the Netherlands, for the treatment of obesity with complications.

- In September 2013, Takeda submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for Haemophilus influenzae type b vaccine TAK-816, which Takeda in-licensed from Novartis of Switzerland.

- In December 2013, Takeda entered an agreement with Natrogen Therapeutics International, Inc. (Natrogen) of the U.S., whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhabit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase II development for the treatment of UC.

- In December 2013, Takeda submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for fomepizole (generic name), which Takeda in-licensed from Paladin Labs Inc. of Canada, for the treatment for ethylene glycol and methanol poisonings

[Joint Research activities]

- In September 2013, Takeda executed a collaboration agreement with Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), and Memorial Sloan-Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College as they formed Tri-TDI. Tri-I TDI's focus is on the early stages of developing compounds that make possible all-important “proof of concept”* studies. They increase the likelihood that targeting a specific biologic pathway can favorably alter the course of a disease.
  *Verification of safety and efficacy of compounds

- In December 2013, Takeda announced that it entered into agreements with Medicines for Malaria Venture (MMV) to study DSM265 and ELQ300, two anti-malarial compounds, with the support of the Global Health Innovative Technology Fund.

[Improvement and Reinforcement of R&D organization]

- In May 2013, Takeda acquired Inviragen, Inc. of the U.S. to advance the Company's commitment to vaccines and global health.

- In August 2013, Takeda concluded the agreement with its wholly-owned subsidiary, Takeda Bio Development Center Limited ("Takeda Bio"), to transfer the current business to Takeda, to enhance oncology development functions in Japan. After the completion of the transfer scheduled in April 2014, Takeda Bio will be dissolved.

(2) Consolidated Financial Position

[Assets]

Total assets as of December 31, 2013 were ¥4,425.8 billion, an increase of ¥470.2 billion compared to the previous fiscal year end. Current assets increased by ¥329.2 billion mainly due to the increase in quick assets accompanied by the fundraising through bonds and loans. Noncurrent assets increased by ¥141.0 billion mainly due to the increase in foreign assets resulting from yen's depreciation and an increase in intangible assets including goodwill accompanied by the acquisition of Inviragen, Inc.

[Liabilities]

Total liabilities as of December 31, 2013 were ¥1,972.5 billion, an increase of ¥240.3 billion compared to the previous fiscal year end. Noncurrent liabilities increased by ¥272.8 billion mainly due to the fundraising through bonds and loans, while current liabilities decreased by ¥32.5 billion mainly due to the payments of income taxes.

[Net Assets]

Total net assets as of December 31, 2013 were ¥2,453.2 billion, an increase of ¥229.9 billion compared to the previous fiscal year end, which despite dividend payments, was mainly due to the increase in foreign currency translation adjustment caused by the yen's depreciation in addition to net income. The shareholders' equity ratio decreased by 0.8 pt. to 53.8% from the previous fiscal year end.

(3) Outlook for Fiscal 2013

The outlook for consolidated results for the full year of fiscal 2013 has been revised from the previous forecast (announced at 2nd quarter of fiscal 2013 financial results announcement on October 31, 2013) as follows, considering the current results and the revised foreign exchange rates.

[Full-year consolidated forecasts (April 1, 2013 to March 31, 2014)]

	Net Sales (¥ billion)	Operating income (¥ billion)	Ordinary income (¥ billion)	Net income (¥ billion)	Earnings per share "EPS" (¥)
Previous forecast (A)	¥1,680.0	¥140.0	¥125.0	¥95.0	¥120.34
Revised forecast in this document (B)	¥1,690.0	¥150.0	¥135.0	¥100.0	¥126.67
Change (B-A)	Increase ¥10.0	Increase ¥10.0	Increase ¥10.0	Increase ¥5.0	
Change	Increase 0.6%	Increase 7.1%	Increase 8.0%	Increase 5.3%	

[Assumptions for the Forecast]
The foreign exchange rates for the 4th quarter are assumed to be US$1 = ¥105 and Euro1 = 140. The average of foreign exchange rates for the full year of fiscal 2013 are assumed to be US$1 = ¥100 and Euro1 = ¥133.

[Forward looking statements]
Our operations are exposed to various risks at present and in the future, such as changes in the business environment and fluctuation of foreign exchange rates. All forecasts in this presentation are based on information currently available to the management, and various factors could cause actual results to differ. We will disclose necessary information in a timely manner when our management believes there will be significant impacts to our consolidated results due to changes in the business environment or other events.

2. Additional Information in Summary

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in consolidation scope):

No applicable event occurred during the period.

(2) Adoption of special accounting treatments for quarterly consolidated financial statements

(i) Calculation of tax expenses

The effective tax rate expected to be imposed on pretax net income (after tax effect accounting) applicable to the tax year in which this reporting period is included was estimated based on reasonable assumptions. Then, tax expenses for the nine month period ended December 31, 2013 were calculated by multiplying the pretax net income for the reporting period by the estimated effective tax rate.

(3) Changes in accounting policies, changes in accounting estimates and restatements

No applicable event occurred during the period.

3. Consolidated Financial Statements for the Nine Month Period Ended December 31, 2013

(1) Consolidated Balance Sheets

Millions of yen

	As of March 31, 2013	As of December 31, 2013
ASSETS		
Current assets		
Cash and deposits	289,613	441,329
Notes and accounts receivable	345,532	427,770
Marketable securities	258,092	291,317
Merchandise and products	108,328	110,932
Work in process	65,168	76,956
Raw materials and supplies	56,035	64,010
Deferred tax assets	240,149	240,985
Other current assets	95,330	135,138
Allowance for doubtful receivables	(3,166)	(4,140)
Total current assets	1,455,081	1,784,297
Noncurrent assets		
Tangible assets	511,101	507,295
Intangible assets		
Goodwill	675,353	748,706
Patent rights	363,057	365,016
Sales rights	582,869	651,079
Other intangible assets	68,456	91,712
Total intangible assets	1,689,735	1,856,513
Investments and other assets		
Investment securities	176,702	174,197
Other assets	123,047	103,600
Allowance for doubtful receivables	(67)	(116)
Total investments and other assets	299,682	277,681
Total noncurrent assets	2,500,518	2,641,489
Total Assets	3,955,599	4,425,786

Millions of yen

	As of March 31, 2013	As of December 31, 2013
LIABILITIES		
Current liabilities		
Notes and accounts payable	118,692	122,927
Short-term loans	1,795	1,422
Income taxes payable	113,430	21,472
Reserve for employees' bonuses	72,338	53,426
Other reserves	10,928	15,790
Other current liabilities	296,449	366,046
Total current liabilities	613,632	581,084
Noncurrent liabilities		
Bond	428,830	548,830
Long-term loans	111,329	241,250
Deferred tax liabilities	322,133	339,950
Reserve for employees' retirement benefits	60,153	71,376
Other reserves	19,842	18,416
Other noncurrent liabilities	176,320	171,636
Total noncurrent liabilities	1,118,608	1391,458
Total liabilities	1,732,240	1,972,542
NET ASSETS		
Shareholders' equity		
Common stock	63,541	63,562
Capital surplus	39,381	38,180
Retained earnings	2,243,113	2,212,006
Treasury stock	(587)	(614)
Total shareholders' equity	2,345,449	2,313,133
Accumulated other comprehensive income		
Unrealized gains/losses on available-for-sale securities	77,960	79,544
Deferred gains/losses on derivatives under hedge accounting	—	(625)
Foreign currency translation adjustments	(264,403)	(10,506)
Total accumulated other comprehensive income	(186,443)	68,413
Stock acquisition rights	934	1,356
Minority interests	63,418	70,341
Total net assets	2,223,359	2,453,243
Total liabilities and net assets	3,955,599	4,425,786

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

Consolidated Statements of Income

Millions of yen

	Nine month period ended December 31, 2012	Nine month period ended December 31, 2013
Net sales	1,189,109	1,286,875
Cost of sales	336,556	359,320
Gross profit	852,553	927,555
Selling, general and administrative expenses		
R&D expenses	231,574	238,194
Other	470,307	520,004
Total selling, general and administrative expenses	701,881	758,198
Operating income	150,672	169,357
Non-operating income		
Interest income	838	777
Dividend income	3,444	3,094
Gains from foreign exchange	2,442	—
Equity in earnings of affiliates	778	754
Rent income	3,590	3,296
Gains on transfer of operation	3,933	4,159
Other non-operating income	3,554	7,724
Total non-operating income	18,580	19,803
Non-operating expenses		
Interest expenses	2,268	3,151
Donations and contributions	2,109	1,300
Losses from foreign exchange	—	3,397
Fair value adjustment of contingent consideration	4,115	8,036
Other non-operating expenses	9,459	16,339
Total non-operating expenses	17,951	32,225
Ordinary income	151,300	156,935
Extraordinary income		
Gains on sales of investment securities	17,039	37,355
Interest on tax refund	11,593	—
Total extraordinary income	28,631	37,355
Extraordinary loss		
Restructuring costs	13,969	14,021
Total extraordinary loss	13,969	14,021
Income before income taxes and minority interests	165,963	180,269
Income taxes	71,161	65,814
Refund for past paid taxes	(45,623)	—
Total income taxes	25,539	65,814
Income before minority interests	140,425	114,455
Minority interests	1,512	3,457
Net income	138,912	110,998

Consolidated Statements of Comprehensive Income

Millions of yen

	Nine month period ended December 31, 2012	Nine month period ended December 31, 2013
Income before minority interests	140,425	114,455
Other comprehensive income		
Unrealized gains/losses on available-for-sale securities	(6,206)	1,618
Deferred gains/losses on derivatives under hedge accounting	(92)	(625)
Foreign currency translation adjustments	65,978	255,942
Share of other comprehensive income of affiliates accounted for using equity method	3,150	113
Total other comprehensive income	62,830	257,049
Comprehensive income	203,255	371,504
[Comprehensive income attributable to]		
Comprehensive income attributable to owners of the parent	201,208	365,854
Comprehensive income attributable to minority interests	2,047	5,650

(3) Notes to Consolidated Financial Statements

(Note regarding going concern assumptions)

Nine month period ended December 31, 2013 (April 1 to December 31, 2013)

No events to be noted for this purpose

(Note regarding significant changes in shareholders' equity)

Nine month period ended December 31, 2013 (April 1 to December 31, 2013)

No events to be noted for this purpose

(Segment Information)

1. Net sales and profit by business segment

Nine month period ended December 31, 2012 (April 1 to December 31, 2012)

Millions of yen

	Business Segments			Total	Adjustments	Amount reported on statement of income
	Ethical Drug	Consumer Healthcare	Other			
Net sales						
Sales to outside customers	1,070,619	53,071	68,760	1,192,450	(3,341)	1,189,109
Intersegment sales and transfers	2,367	298	4,802	7,467	(7,467)	—
Total	1,072,987	53,369	73,561	1,199,917	(10,808)	1,189,109
Segment profit	129,644	13,366	9,212	152,222	(1,550)	150,672

Nine month period ended December 31, 2013 (April 1 to December 31, 2013)

Millions of yen

	Business Segments			Total	Adjustments	Amount reported on statement of income
	Ethical Drug	Consumer Healthcare	Other			
Net sales						
Sales to outside customers	1,163,386	57,282	69,264	1,289,931	(3,057)	1,286,875
Intersegment sales and transfers	2,272	774	4,663	7,710	(7,710)	—
Total	1,165,657	58,056	73,927	1,297,641	(10,767)	1,286,875
Segment profit	143,043	16,596	10,948	170,586	(1,230)	169,357

(Note) Segment profit equals operating income on each segment.

2. Information regarding regions

Net sales
Nine month period ended December 31, 2012 (April 1 to December 31, 2012)

Millions of yen

Japan	North America		Europe	Russia /CIS	Latin America	Asia	Other	Total
		United States						
571,024	282,933	270,586	179,365	48,359	46,325	44,942	16,161	1,189,109

Nine month period ended December 31, 2013 (April 1 to December 31, 2013)

Millions of yen

Japan	North America		Europe	Russia /CIS	Latin America	Asia	Other	Total
		United States						
570,014	281,095	263,518	224,708	66,944	59,211	62,819	22,084	1,286,875

(Note)
1. “Net Sales” is classified into countries or regions based on the customer location.
2. Effective from the three month period ended September 30, 2013, the Company changed the regional classification for the purpose of providing more detailed sales information (previous “Americas” was divided into “North America” and “Latin America” and previous “Europe” was divided into “Europe” and “Russia/CIS”). For fair comparison over the same period last year, the amounts reported in the same period of last year were modified according to the new classification.
3. “Other” region includes Middle East, Oceania and Africa.

(Sales Results (Sales to outside customers))

Nine month period ended December 31, 2012 (April 1 to December 31, 2012)

Millions of yen

Ethical Drug			Consumer Healthcare	Other	Adjustments	Amount reported on statement of income	[Royalties]
(Japan)	(Overseas)	Subtotal					
459,241	611,378	1,070,619	53,071	68,760	(3,341)	1,189,109	[34,750]

Nine month period ended December 31, 2013 (April 1 to December 31, 2013)

Millions of yen

Ethical Drug			Consumer healthcare	Other	Adjustments	Amount reported on statement of income	[Royalties]
(Japan)	(Overseas)	Subtotal					
454,135	709,251	1,163,386	57,282	69,264	(3,057)	1,286,875	[64,462]

4. Supplemental Information

(1) Ethical Drugs Sales [Consolidated]

Billions of yen

	Nine month period ended December 31, 2012	Nine month period ended December 31, 2013	Change over the same period of the previous year		Three month period ended December 31, 2012	Three month period ended December 31, 2013	Change over the same period of the previous year	
			Amount	Increase (decrease) in percent			Amount	Increase (decrease) in percent
Domestic sales	460.3	454.8	(5.5)	(1.2%)	163.1	163.3	0.2	0.1%
Overseas sales	573.8	640.2	66.5	11.6%	181.8	222.9	41.2	22.6%
North America	270.1	252.8	(17.3)	(6.4%)	75.9	86.8	10.9	14.4%
United States	258.0	235.7	(22.3)	(8.6%)	71.6	80.5	8.9	12.4%
Europe	152.6	181.2	28.7	18.8%	50.3	61.3	11.0	21.9%
Russia/CIS	48.3	66.9	18.6	38.5%	18.8	25.7	6.8	36.4%
Latin America	45.9	58.8	12.8	28.0%	16.8	21.0	4.2	25.1%
Asia	41.6	59.4	17.8	42.7%	15.0	21.2	6.3	41.9%
Other	15.3	21.2	5.9	38.5%	5.1	7.0	1.9	37.9%
Royalty Income and Service Income	38.9	70.6	31.7	81.6%	16.1	29.2	13.0	80.7%
Domestic	1.3	1.6	0.3	25.2%	0.6	0.6	(0.0)	(7.6%)
Overseas	37.6	69.0	31.4	83.5%	15.5	28.6	13.1	84.4%
Total sales	1,073.0	1,165.7	92.7	8.6%	361.0	415.4	54.4	15.1%

(Note)

1. Sales amount includes intersegment sales.
2. Effective from the three month period ended September 30, 2013, the Company changed the regional classification for the purpose of providing more detailed sales information (previous “Americas” was divided into “North America” and “Latin America” and previous “Europe” was divided into “Europe” and "Russia/CIS"). For fair comparison over the same period last year, the amounts reported in the same period of last year were modified according to the new classification.
3. “Other” region includes Middle East, Oceania and Africa.

Ratio of Overseas sales	57.0%	60.8%	54.6%	60.5%

Foreign exchange rates

yen

	Nine month period ended December 31, 2012	Nine month period ended December 31, 2013	Three month period ended December 31, 2012(*)	Three month period ended December 31, 2013(*)
US$ average rate	79.8	98.7	79.8	99.7
Euro average rate	102.0	130.8	103.3	135.8

(*) Sales amounts of foreign affiliates for three month period ended December 31 are calculated on net-basis (“cumulative nine months sales” minus “cumulative six months sales”) in Japanese Yen. Therefore, the indicated average rates for the three month period ended December 31 are not applied to the translation of sales amounts of foreign affiliates for the same period. They are indicated for a reference purpose only.

(2) Ethical Drugs: Global sales of major products

Billions of yen

	Nine month period ended December 31, 2012	Nine month period ended December 31, 2013	Change over the same period of the previous year		Three month period ended December 31, 2012	Three month period ended December 31, 2013	Change over the same period of the previous year	
			Amount	Increase (decrease) in percent			Amount	Increase (decrease) in percent
Candesarta	132.9	122.9	(9.9)	(7.5%)	43.7	40.6	(3.1)	(7.0%)
Leuprorelin	87.7	95.9	8.2	9.4%	30.3	31.8	1.5	4.8%
Lansoprazol	85.6	90.1	4.5	5.2%	29.8	30.2	0.4	1.4%
Pantoprazol	56.5	77.2	20.7	36.7%	19.7	29.3	9.6	48.6%
Velcade	53.9	71.4	17.5	32.5%	18.2	24.1	5.9	32.3%
Colcrys	22.9	38.1	15.3	66.7%	10.5	12.4	1.9	18.0%
Dexilant	23.5	36.2	12.7	54.2%	8.4	12.6	4.2	50.8%
Nesina	25.8	31.0	5.3	20.4%	10.5	12.6	2.2	20.9%
Pioglitazone	109.2	29.5	(79.7)	(73.0%)	17.2	9.5	(7.7)	(44.7%)
Actovegin	14.2	20.6	6.4	44.8%	5.9	8.1	2.2	36.8%
Uloric	12.8	19.4	6.7	52.1%	4.7	7.0	2.3	48.6%
Amitiza	16.5	18.5	2.0	12.2%	5.8	6.4	0.6	10.9%
Calcium	11.0	13.8	2.8	25.4%	4.1	5.0	0.9	22.9%
Tachosil	10.1	12.7	2.6	26.2%	3.6	4.7	1.1	28.9%
Adcetris	2.8	9.5	6.7	243.7%	1.0	3.3	2.3	224.5%
Daxas	2.2	2.9	0.8	35.4%	0.8	1.0	0.3	36.2%

(3) Ethical Drugs: Overseas sales of major products (Regional basis)

Billions of yen

	Nine month period ended December 31, 2012	Nine month period ended December 31, 2013	Change over the same period of the previous year		Three month period ended December 31, 2012	Three month period ended December 31, 2013	Change over the same period of the previous year	
			Amount	Increase (decrease) in percent			Amount	Increase (decrease) in percent
Candesartan (Note 2)								
North America, Latin America, Europe, Russia/CIS, Asia and Other regions....	28.8	23.0	(5.8)	(20.1%)	6.9	6.3	(0.6)	(8.6%)
Leuprorelin								
North America and Latin America.....	10.7	12.7	2.0	19.1%	3.5	3.7	0.2	4.7%
Europe and Russia/CIS....	20.5	24.5	4.0	19.6%	6.9	8.2	1.3	19.5%
Asia and Other regions....	5.7	7.4	1.7	30.6%	2.0	2.4	0.4	17.1%
Lansoprazole								
North America and Latin America.....	19.6	20.3	0.7	3.8%	6.2	6.3	0.1	1.2%
Europe and Russia/CIS....	7.9	9.4	1.5	19.2%	3.1	3.0	(0.1)	(2.0%)
Asia and Other regions....	4.5	6.4	1.9	41.8%	1.6	2.1	0.5	28.1%
Pantoprazole								
North America and Latin America.....	21.6	30.6	9.0	41.5%	7.7	13.3	5.6	73.3%
Europe and Russia/CIS....	22.1	27.8	5.7	25.9%	7.5	10.1	2.6	34.4%
Asia and Other regions....	12.7	18.8	6.0	47.2%	4.5	5.9	1.4	30.5%
Pioglitazone								
North America and Latin America.....	84.2	6.5	(77.8)	(92.3%)	9.2	1.7	(7.5)	(81.9%)
Europe and Russia/CIS....	6.2	5.8	(0.4)	(6.1%)	1.9	2.2	0.3	18.7%
Asia and Other regions....	3.4	4.7	1.2	35.9%	1.1	1.4	0.4	37.6%

(Note)

1. This chart shows the major overseas product sales classified as "North America and Latin America," "Europe and Russia/CIS" and "Asia and Other regions" and does not include sales in Japan.
2. The sales of *Candesartan* are shown in one area (North America, Latin America, Europe, Russia/CIS, Asia and Other regions), because export sales of *Candesartan* to licensees are recorded under a single route.

(4) Ethical Drugs: Domestic sales of major products

Billions of yen

Product name	Launched Month/Year	Category	**Nine month period ended December 31, 2012**	**Nine month period ended December 31, 2013**	Change over the same period of the previous year		Three month period ended December 31, 2012	Three month period ended December 31, 2013	Change over the same period of the previous year	
					Amount	Increase (decrease) in percent			Amount	Increase (decrease) in percent
Blopress (candesartan)	6/1999	Hypertension	104.1	100.0	(4.1)	(4.0%)	36.8	34.3	(2.5)	(6.7%)
<Ecard>	3/2009	Hypertension	9.7	9.0	(0.7)	(6.9%)	3.4	3.1	(0.3)	(10.0%)
<Unisia>	6/2010	Hypertension	16.9	19.4	2.5	14.8%	6.3	6.9	0.6	10.3%
Takepron (lansoprazole)	12/1992	Peptic ulcers	53.7	54.0	0.3	0.6%	18.9	18.8	(0.0)	(0.3%)
Leuplin (leuprorelin)	9/1992	Prostate cancer, breast cancer and endometriosis	50.8	51.2	0.4	0.9%	17.8	17.5	(0.4)	(2.2%)
Enbrel	3/2005	Rheumatoid arthritis	33.3	34.4	1.0	3.1%	11.5	11.9	0.4	3.6%
Nesina	6/2010	Diabetes	25.8	29.5	3.7	14.5%	10.5	11.6	1.2	11.4%
<Liovel>	9/2011	Diabetes	3.5	6.4	2.9	84.9%	1.7	2.6	0.9	55.1%
Azilva	5/2012	Hypertension	2.1	15.9	13.7	638.8%	0.2	7.9	7.7	—
Vectibix	6/2010	Colorectal cancer	14.7	14.8	0.1	0.8%	5.1	5.2	0.2	3.3%
Basen	9/1994	Diabetes	15.3	12.9	(2.4)	(15.6%)	5.1	4.3	(0.8)	(16.6%)
Actos (pioglitazon)	12/1999	Diabets	15.3	12.5	(2.8)	(18.1%)	5.1	4.2	(0.9)	(17.8%)
Benet	5/2002	Osteoporosis	10.4	9.1	(1.3)	(12.6%)	3.5	3.1	(0.4)	(12.0%)
Reminyl	3/2011	Alzheimer-type dementia	6.2	9.1	2.8	45.1%	2.5	3.3	0.8	33.5%
Rozerem	7/2010	Insomnia	3.3	4.5	1.1	33.4%	1.3	1.6	0.4	30.0%
Lotriga	1/2013	Hyperlipidemia	—	3.5	3.5	—	—	1.7	1.7	—

(5) Consumer Healthcare: Sales of major products

Billions of yen

Product name	**Nine month period ended December 31, 2012**	**Nine month period ended December 31, 2013**	Change over the same period of the previous year		Three month period ended December 31, 2012	Three month period ended December 31, 2013	Change over the same period of the previous year	
			Amount	Increase (decrease) in percent			Amount	Increase (decrease) in percent
Alinamin tablets	12.3	15.0	2.7	21.8%	4.4	5.7	1.2	27.9%
Alinamin health tonics	11.9	12.5	0.6	4.7%	3.9	4.2	0.3	6.8%
Benza	8.6	9.0	0.4	4.6%	3.3	3.0	(0.3)	(9.1%
Biofermin	6.3	6.5	0.2	2.4%	2.3	2.3	0.0	1.8%
Borraginol	3.3	3.3	(0.0)	(0.1%)	1.3	1.3	0.0	1.7%

(6) Development activities

■ US/EU/Jpn

Development code/product name <generic name>	Drug Class (administration route)	Indications	Stage		In-house/ In-license
TAK-390MR <dexlansoprazole>	Proton pump inhibitor (oral)	Erosive esophagitis (healing and maintenance), Non-erosive gastro-esophageal reflux disease	EU	Approved (Sep 13)*1	In-house
SYR-322 <alogliptin>	DPP-4 inhibitor (oral)	Diabetes mellitus	EU	Approved (Sep 13)	In-house
		Diabetes mellitus (Fixed-dose combination with metformin)	EU	Approved (Sep 13)	
		Diabetes mellitus (Fixed-dose combination with pioglitazone)	EU	Approved (Sep 13)	
ATL-962 <cetilistat>	Lipase inhibitor (oral)	Obesity with both type 2 diabetes mellitus and dyslipidemia	Jpn	Approved (Sep 13)	In-license (Norgine BV)*2
Lu AA21004 <vortioxetine>	Multimodal anti-depressant (oral)	Major depressive disorder	US Jpn	Approved (Sep 13) P-III	In-license (Lundbeck)
		Generalized anxiety disorder	US	P-III	
SGN-35 <brentuximab vedotin>	CD30 monoclonal antibody-drug conjugate (injection)	Relapsed or refractory Hodgkin lymphoma	Jpn	Approved (Jan 14)	In-license (Seattle Genetics)
		Relapsed or refractory anaplastic large cell lymphoma	Jpn	Approved (Jan 14)	
		Relapsed cutaneous T-cell lymphoma	EU	P-III	
		Post-ASCT Hodgkin lymphoma	EU	P-III	
		Front line Hodgkin lymphoma	EU	P-III	
		Front line mature T-cell lymphoma	EU Jpn	P-III P-III	
MLN0002 <vedolizumab>	Humanized monoclonal antibody against α4β7 integrin (injection)	Ulcerative colitis	US EU Jpn	Filed (Jun 13) Filed (Mar 13) P-III	In-house
		Crohn's disease	US EU Jpn	Filed (Jun 13) Filed (Mar 13) P-III	
<lurasidone hydrochloride>	Atypical antipsychotic agent (oral)	Schizophrenia	EU	Filed (Sep 12)	In-license (Dainippon Sumitomo)
		Bipolar disorder	EU	P-III	
BLB-750	Influenza vaccine (injection)	Prevention of pandemic influenza	Jpn	Filed (Mar 13)	In-license (Baxter)
TAK-816	Hib vaccine (injection)	Prevention of infectious disease caused by Haemophilus influenza Type b (Hib)	Jpn	Filed (Sep 13)	In-license (Novartis)
Contrave® <naltrexone SR /bupropion SR>	Mu-opioid receptor antagonist and dopamine/norepinephrine re-uptake inhibitor (oral)	Obesity	US	Filed (Dec 13)	In-license (Orexigen)
fomepizole	Alcohol dehydrogenase inhibitor (injection)	Ethylene glycol and methanol poisonings	Jpn	Filed (Dec 13)	In-license (Paladin Labs)
TAK-700 <orteronel>	Non-steroidal androgen synthesis inhibitor (oral)	Prostate cancer	US EU Jpn	P-III P-III P-III	In-house
MLN9708 <ixazomib citrate>	Proteasome inhibitor (oral)	Multiple myeloma	US EU	P-III P-III	In-house
		Relapsed or refractory multiple myeloma	Jpn	P-III	
		Relapsed or refractory primary (AL) amyloidosis	US EU	P-III P-III	
		Solid tumors	US	P-I	

*1 Approved in 16 countries in the EU by the decentralized procedure

*2 Alizyme assigned ATL-962 (cetilistat) business to Norgine BV on Oct 15th, 2009

Development code/product name <generic name>	Drug Class (administration route)	Indications	Stage		In-house/ In-license
MLN8237 <alisertib>	Aurora A kinase inhibitor (oral)	Relapsed or refractory peripheral T-cell lymphoma	US EU	P-III P-III	In-house
		Diffuse large B-cell lymphoma, Non-small cell lung cancer, Small cell lung cancer, Gastroesophageal cancer, Head and neck cancer, Breast cancer, Ovarian cancer	US EU	P-II P-II	
		Non-Hodgkin lymphoma	Jpn	P-I	
		Solid tumors	Jpn	P-I	
SYR-472 <trelagliptin>	DPP-4 inhibitor (oral)	Diabetes mellitus	Jpn US EU	P-III P-II P-II	In-house
TAK-438 <vonoprazan>	Potassium-competitive acid blocker (oral)	Acid-related diseases (GERD, Peptic ulcer, etc.)	Jpn	P-III	In-house
<motesanib diphosphate>	VEGFR1-3, PDGFR, c-Kit inhibitor (oral)	Advanced non-squamous non-small cell lung cancer	Jpn	P-III	In-license (Amgen)
AMG 386 <trebananib>	Anti-angiopoietin peptibody (injection)	Ovarian cancer	Jpn	P-III	In-license (Amgen)
<peginesatide>	Synthetic, peptide-based erythropoiesis-stimulating agent (injection)	Anaemia associated with chronic kidney disease in adult patients undergoing dialysis	EU	P-III*3	In-license (Affymax)
DENVax	Dengue vaccine (injection)	Prevention of dengue fever caused by dengue virus	-	P-II	In-house
TAK-385 <relugolix>	LH-RH antagonist (oral)	Endometriosis, Uterine fibroids	Jpn	P-II	In-house
		Prostate Cancer	-	P-I	
TAK-361S	Quadruple vaccine (injection)	Prevention of infectious disease caused by Diphtheria, Pertussis, Tetanus, Polio	Jpn	P-II	In-license (Japan Polio)
Natura-alpha	Immunoregulatory agent (oral)	Ulcerative colitis	-	P-II	In-license (Natrogen)
Norovirus vaccine	Norovirus vaccine (injection)	Prevention of acute gastroenteritis (AGE) caused by norovirus	-	P-I/II	In-house
TAK-733 < - >	MEK inhibitor (oral)	Solid tumors	-	P-I	In-house
TAK-272 < - >	Direct renin inhibitor (oral)	Hypertension	-	P-I	In-house
TAK-063 < - >	PDE10A inhibitor (oral)	Schizophrenia	-	P-I	In-house
TAK-137 < - >	AMPA receptor potentiator (oral)	Psychiatric disorders and neurological diseases	-	P-I	In-house
TAK-659 < - >	SYK kinase inhibitor (oral)	Hematologic malignancies, Solid tumors	-	P-I	In-house
INV21	EV71 vaccine (injection)	Prevention of hand, foot and mouth disease caused by enterovirus 71	-	P-I	In-house
MLN4924 < - >	NEDD 8 activating enzyme inhibitor (injection)	Advanced malignancies	-	P-I	In-house
MLN0128 < - >	mTORC1/2 inhibitor (oral)	Multiple myeloma, Waldenstrom's macroglobulinemia, Solid tumors	-	P-I	In-house
MLN1117 < - >	PI3Kα isoform inhibitor (oral)	Solid tumors	-	P-I	In-house

*3 Resubmission subject to outcome of ongoing investigation in the US

Development code/ product name <generic name>	Drug Class (administration route)	Indications	Stage		In-house/ In-license
MLN0264 < - >	Antibody-Drug Conjugate targeting GCC (injection)	Advanced gastrointestinal malignancies	-	P-I	In-house
MLN2480 < - >	pan-Raf kinase inhibitor (oral)	Solid tumors	-	P-I	In-license (Sunesis)
MT203 <namilumab>	GM-CSF monoclonal antibody (injection)	Rheumatoid arthritis	EU	P-I	In-licence (Amgen)*4
Lu AA24530 < - >	Multimodal anti-depressant (oral)	Major depressive disorder, Generalized anxiety disorders	US Jpn	P-I P-I	In-license (Lundbeck)
AMG 403 <fulranumab>	Human monoclonal antibody against human Nerve Growth Factor (NGF) (injection)	Pain	Jpn	P-I	In-license (Amgen)
ITI-214 < - >	PDE1 inhibitor (oral)	Cognitive impairment associated with schizophrenia	-	P-I	In-license (Intra-Cellular)

*4 Deal made with Micromet; on Mar 7th, 2012, Micromet became a wholly owned subsidiary of Amgen

■ Additional indications/formulations of compounds

Development code/ product name <generic name> Brand name (country / region)	Drug Class	Indications or formulations	Stage	In-house/ In-license
AG-1749 <lansoprazole> Takepron® (Jpn) Prevacid® (US) Ogast®, etc. (EU)	Proton pump inhibitor	Fixed-dose combination with low-dose aspirin	Jpn Filed (Mar 13)	In-house
TAK-536 <azilsartan> Azilva® (Jpn)	Angiotensin II receptor blocker	Hypertension (Fixed-dose combination with amlodipine besilate)	Jpn Filed (Apr 13)	In-house
Rienso® <ferumoxytol>	IV iron	Iron deficiency anemia from all causes in patients who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used	EU Filed (Jun 13)	In-license (AMAG)
TAP-144-SR <leuprorelin acetate> Leuplin® (Jpn) Lupron Depot® (US) Enantone®, etc. (EU)	LH-RH agonist	Prostate cancer, Premenopausal breast cancer (6-month formulation)	Jpn P-III	In-house
TAK-375SL <ramelteon> Rozerem® (US, Jpn)	MT1/MT2 receptor agonist	Bipolar (sublingual formulation)	US P-III	In-house
VELCADE® <bortezomib>	Proteasome inhibitor	Front line mantle cell lymphoma Relapsed diffuse large B-cell lymphoma	US P-III US P-II	In-house
AD-4833/TOMM40	Insulin sensitizer/ Biomarker assay	Delay of onset of mild cognitive impairment due to Alzheimer's disease	US P- III EU P- III	In-license (Zinfandel)
AMITIZA® <lubiprostone>	Chloride channel activator	Liquid formulation Pediatric functional constipation	US P- III US P- III	In-license (Sucampo)

■ Recent progress in stage **Progress in stage since release of FY2012 results (May 9th, 2013)**

Development code/ product name <generic name>	Indications	Country/Region	Progress in stage
TAK-390MR <dexlansoprazole>	Erosive esophagitis (healing and maintenance), Non-erosive gastro-esophageal reflux disease	EU	Approved (Sep 13)
SYR-322 <alogliptin>	Diabetes mellitus	EU	Approved (Sep 13)
SYR-322 <alogliptin>	Diabetes mellitus (Fixed-dose combination with metformin)	EU	Approved (Sep 13)
SYR-322 <alogliptin>	Diabetes mellitus (Fixed-dose combination with pioglitazone)	EU	Approved (Sep 13)
ATL-962 <cetilistat>	Obesity with both type 2 diabetes mellitus and dyslipidemia	Jpn	Approved (Sep 13)
Lu AA21004 <vortioxetine>	Major depressive disorder	US	Approved (Sep 13)
MLN0002 <vedolizumab>	Ulcerative colitis	US	Filed (Jun 13)
MLN0002 <vedolizumab>	Crohn's disease	US	Filed (Jun 13)
Rienso® <ferumoxytol>	Iron deficiency anemia from all causes in patients who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used	EU	Filed (Jun 13)
TAK-816	Prevention of infectious disease caused by Haemophilus influenza Type b (Hib)	Jpn	Filed (Sep 13)
AD-4833/TOMM40	Delay of onset of mild cognitive impairment due to Alzheimer's disease	US/EU	P-III
AMITIZA® <lubiprostone>	Liquid formulation	US	P-III
SGN-35 <brentuximab vedotin>	Front line mature T-cell lymphoma	Jpn	P-III
TAK-137 < - >	Psychiatric disorders and neurological diseases	-	P-I
SGN-35 <brentuximab vedotin>	Relapsed or refractory Hodgkin lymphoma	Jpn	Approved (Jan 14)
SGN-35 <brentuximab vedotin>	Relapsed or refractory anaplastic large cell lymphoma	Jpn	Approved (Jan 14)
Contrave® <naltrexone SR / bupropion SR>	Obesity	US	Filed (Dec 13)
fomepizole	Ethylene glycol and methanol poisonings	Jpn	Filed (Dec 13)
MLN0002 <vedolizumab>	Ulcerative colitis	Jpn	P-III
MLN0002 <vedolizumab>	Crohn's disease	Jpn	P-III
MLN9708 <ixazomib citrate>	Relapsed or refractory multiple myeloma	Jpn	P-III
AMITIZA® <lubiprostone>	Pediatric functional constipation	US	P-III
TAK-659 < - >	Hematologic malignancies, Solid tumors	-	P-I

Progress in stage since the announcement of FY2013 2Q results (October 31st, 2013) are listed under the bold dividing line

■ Discontinued projects Discontinued since release of FY2012 results (May 9th, 2013)

Development code/ product name <generic name>	Indications (Stage)	Reason
AMG 479 <ganitumab>	Metastatic pancreas cancer (Jpn P-III)	Independent Data Monitoring Committee (DMC) reviewed the interim analysis and concluded that it was unlikely to meet the primary endpoint
TAK-491 <azilsartan medoxomil>	Hypertension (fixed-dose combination with chlorthalidone) (EU P-III)	Discontinued due to a reassessment of the marketing opportunity in the EU
TAK-428 < - >	Diabetic neuropathy (US/EU P-II)	Discontinued based on reassessment of portfolio prioritization
TAK-390MR <dexlansoprazole>	Erosive esophagitis (healing and maintenance), Non-erosive gastro-esophageal reflux disease (Jpn P-II)	Discontinued due to advanced progress of TAK-438 program in Japan
TAK-329 < - >	Diabetes (P-I)	Discontinued due to the clinical data failing to meet the criteria for stage-up
TAK-875 <fasiglifam>	Diabetes (P-III)	Discontinued due to concerns about liver safety

Projects discontinued since the announcement of FY2013 2Q results (October 31st, 2013) are listed under the bold dividing line

■ Revised collaboration agreement Revised since release of FY2012 results (May 9th, 2013)

Development code/ product name <generic name>	Indications (Stage)	Reason
Sovrima® <idebenone>	Friedreich's ataxia, Duchenne muscular dystrophy (EU P-III)	Rights for Sovrima returned to Santhera upon Santhera's request and due to a reassessment of portfolio prioritization
<veltuzumab>	Systemic lupus erythematosus (US/EU P-II)	The agreement on veltuzumab with Immunomedics terminated; an arbitration proceeding between the parties is currently on-going

■ Filings and Approvals in Regions other than US/EU/Jpn

Region	Country	Development code / product name (stage)
Americas Ex. US	Argentina	TAK-491*5 (Filed Oct 12), SGN-35 (Filed Jun 13), SYR-322 (Filed Aug 13), SYR-322/metformin (Filed Sep 13), SYR-322/pioglitazone (Filed Sep 13)
	Brazil	SYR-322 (Approved Dec 13), TAK-491 (Filed Nov 11), SYR-322/metformin (Filed Jun 12), TAK-491/chlorthalidone (Filed Jun 12), SYR-322/pioglitazone (Filed Dec 12)
	Colombia	DAXAS*6 (Approved Jul 13), TAK-491 (Filed Aug 12), SYR-322 (Filed Sep 12), TAK-491/chlorthalidone (Filed Oct 12),SYR-322/pioglitazone (Filed Oct 12), SYR-322/metformin (Filed Nov 12), TAK-390MR (Filed Dec 12(30mg)/Mar 13(60mg)), SGN-35 (Filed Feb 13)
	Ecuador	DAXAS (Approved Nov 13), SYR-322 (Filed Nov 13), SYR-322/pioglitazone (Filed Nov 13)
	Peru	SYR-322 (Filed Dec 13), SYR-322/pioglitazone (Filed Dec 13)
	Venezuela	mifamurtide*7 (Approved Apr 13), DAXAS (Approved Jul 13), TAK-390MR (Filed Sep 13), SGN-35 (Filed Nov 13)
Europe Ex. EU	Albania	DAXAS (Approved Apr 13)
	Iceland	SYR-322 (Approved Oct 13), SYR-322/metformin (Approved Oct 13), SYR-322/pioglitazone (Approved Oct 13)
	Montenegro	DAXAS (Approved Oct 13)
	Norway	SYR-322 (Approved Oct 13), SYR-322/metformin (Approved Oct 13), SYR-322/pioglitazone (Approved Oct 13)
	Serbia	SGN-35 (Filed Dec 13)
	Switzerland	lurasidone hydrochloride (Approved Aug 13), SYR-322 (Approved Nov 13), SYR-322/metformin (Approved Nov 13), TAK-390MR (Filed Sep 12), TAK-491/chlorthalidone (Filed Jan 13), MLN0002 (Filed May 13)
Russia/CIS	Belarus	DAXAS (Filed Apr 13)
	Kazakhstan	TAK-491 (Filed Jan 13), SGN-35 (Filed Sep 13)
	Russia	TAK-491 (Filed Apr 13), SYR-322 (Filed Dec 13), SYR-322/metformin (Filed Dec 13)
	Ukraine	mifamurtide (Approved Jul 13), SGN-35 (Approved Oct 13), TAK-491 (Filed Dec 12), SYR-322/metformin (Filed Dec 13)
Asia Ex. Jpn	China	SYR-322 (Approved Jul 13), DAXAS (Filed Dec 11), SGN-35 (Filed May 13)
	Hong Kong	SGN-35 (Filed Feb 13), TAK-491/chlorthalidone (Filed Mar 13), SYR-322 (Filed Dec 13), SYR-322/metformin (Filed Dec 13)
	Indonesia	SYR-322 (Filed Jan 11), TAK-491 (Filed Feb 12), TAK-491/chlorthalidone (Filed Jul 12), TCV-116*8/amlodipine besilate (Filed Oct 12)
	Macau	SYR-322 (Approved Oct 13), SYR-322/metformin (Approved Nov 13), SYR-322/pioglitazone (Approved Nov 13)
	Malaysia	TAK-390MR (Filed Sep 12), TAK-491 (Filed Jan 13), TAK-491/chlorthalidone (Filed Apr 13), SYR-322 (Filed Dec 13), SYR-322/metformin (Filed Dec 13), SYR-322/pioglitazone (Filed Dec 13)
	Philippines	TAK-491/chlorthalidone (Filed Sep 13)
	Singapore	SGN-35 (Approved Jan 14), TAK-390MR (Filed Oct 12), TAK-491 (Filed Dec 12), TAK-491/chlorthalidone (Filed Mar 13)
	S. Korea	SYR-322 (Approved May 13), SGN-35 (Approved May 13), SYR-322/pioglitazone (Filed Nov 13)
	Taiwan	TAK-491 (Approved Jun 13), SYR-322 (Filed Mar 11), TAK-491/chlorthalidone (Filed May 12), TCV-116/amlodipine besilate (Filed Nov 12), SGN-35 (Filed Mar 13), SYR-322/metformin (Filed Nov 13), SYR-322/pioglitazone (Filed Nov 13)
	Thailand	TAK-390MR (Approved Jun 13), TAK-491/chlorthalidone (Filed Jun 12), TCV-116/amlodipine besilate (Filed Aug 12), SYR-322/pioglitazone (Filed Mar 13), SGN-35 (Filed May 13)
	Vietnam	DAXAS (Approved Apr 13)
Others	Australia	SYR-322 (Approved Sep 13), SYR-322/metformin (Approved Oct 13), SGN-35 (Approved Dec 13), MLN0002 (Filed Jun 13)
	Algeria	DAXAS (Filed Jul 13)
	Botswana	DAXAS (Approved Sep 13)
	Egypt	DAXAS (Filed Jan 12), TAK-491 (Filed Apr 13), TAK-491/chlorthalidone (Filed Jun 13), SYR-322 (Filed Jul 13), SYR-322/pioglitazone (Filed Aug 13), SYR-322/metformin (Filed Sep 13)
	India	DAXAS (Filed Mar 13)
	Israel	SGN-35 (Filed Aug 13)
	Jordan	DAXAS (Filed Mar 13)
	Kenya	DAXAS (Approved Oct 13)
	Mauritius	DAXAS (Approved May 13)
	Saudi Arabia	DAXAS (Approved Aug 13)
	South Africa	SGN-35 (Filed Jul 13), SYR-322 (Filed Dec 13), SYR-322/metformin (Filed Dec 13)
	Tanzania	DAXAS (Filed Sep 11)
	Uganda	DAXAS (Filed Apr 11)
	UAE	TAK-491 (Filed May 13), TAK-390MR (Filed Jun 13)
	Zambia	DAXAS (Filed Feb 12)

*5 **TAK-491 <azilsartan medoxomil>** Angiotensin II receptor blocker (oral) for the treatment of Hypertension

*6 **DAXAS® <roflumilast>** PDE4 inhibitor (oral) for the treatment of Chronic Obstructive Pulmonary Disease

*7 **<mifamurtide>** Immunostimulant (injection) for the treatment of Non-metastatic osteosarcoma

*8 **TCV-116 <candesartan cilexetil>** Angiotensin II receptor blocker (oral) for the treatment of Hypertension